



Jacopo Giuliani

📍 Home-IT:

✉ Email-IT:

☎ Phone-IT: (+39)

♂ Gender-IT: Male-IT Date of birth-IT:

🇮🇹 Nationality-IT:

LANGUAGE SKILLS-IT

Mother tongue(s)-IT: Italian-IT

Other language(s)-IT:

English-IT

LISTENING-IT B2 READING-IT B2 WRITING-IT B2

SPOKEN PRODUCTION-IT B2 SPOKEN INTERACTION-IT B2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user-IT

EDUCATION AND TRAINING-IT

[09/10/2006 – Current-IT]

Laurea in Medicina e Chirurgia

Università degli Studi di Ferrara www.unife.it

City-IT: Ferrara | Country-IT: Italy-IT | | Final grade-IT: 110/110 e lode

Abilitazione all'esercizio professionale (seconda sessione del 2006)

Università degli Studi di Ferrara

City-IT: Ferrara | Country-IT: Italy-IT |

Iscrizione all'Albo dei Chirurghi e degli Odontoiatri della Provincia di Rovigo (dal 18/04/2017, numero di iscrizione 1632)

City-IT: Rovigo | Country-IT: Italy-IT |

[26/07/2011 – Current-IT]

Specializzazione in Oncologia – Oncologia Medica

Università degli Studi di Ferrara www.unife.it

City-IT: Ferrara | Country-IT: Italy-IT | | Final grade-IT: 50/50 e lode

[16/02/2022 – Current-IT]

Master in Health Technology Assessment – COPTHA IX Edizione

LIUC Business School www.liucbs.it

City-IT: Castellanza (VA) | Country-IT: Italy-IT |

HONOURS AND AWARDS- IT

Premio di Studio "Giuliana Ferroni Vallese", Anno 2006 (Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri di Rovigo)

Premio di Studio "Mario e Lina Austoni", Anno Accademico 2006/2007 (Università degli Studi di Padova)

Premio di Studio "Giuseppe Previtali", Anno 2008 (Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri di Rovigo)

Premio di Laurea "Giovanna Elisa Zanetti A.A. 2008/2009" (Università degli Studi di Ferrara)

WORK EXPERIENCE-IT

[01/06/2016 – Current-IT]

Dirigente Medico

Azienda ULSS 9 Scaligera

City-IT: Verona | Country-IT: Italy-IT

- contratto di lavoro a tempo indeterminato, tempo pieno
- disciplina Oncologia Medica

[01/04/2013 – 31/05/2016]

Dirigente Medico

dapprima Azienda ULSS 21 di Legnago, successivamente Azienda ULSS 9 Scaligera

City-IT: Verona | Country-IT: Italy-IT

- contratto di lavoro a tempo determinato
- disciplina Oncologia Medica

[01/08/2012 – 31/03/2013]

incarico libero professionale

Azienda ULSS 21 di Legnago (VR)

City-IT: Legnago (VR)

- prestazioni connesse alle attività del Nucleo di Cure Palliative

[01/09/2011 – 19/06/2012]

incarico libero professionale

Azienda USL di Ferrara

City-IT: Ferrara | Country-IT: Italy-IT

- Attività in qualità di Medico Oncologo finalizzata al Programma "Percorso nutrizionale in oncologia"

COMMUNICATION AND INTERPERSONAL SKILLS- IT

Capacità e competenze professionali

Sostenibilità ed adattabilità, associate a competenze tecniche e relazionali. Tra le competenze tecniche si evidenziano l'autonomia nella presa in carico del paziente oncologico per la fase diagnostica e di trattamento (chemioterapia, terapie a bersaglio molecolare, agenti immunomodulanti) e di follow-up di tutte le principali neoplasie, comprese le terapie di supporto e palliative. Per quanto concerne le competenze relazionali si evidenziano sia la capacità di creare un clima di collaborazione con le diverse figure professionali sia lo sviluppo di empatia nei confronti di pazienti e familiari, accompagnati da chiarezza espositiva nei confronti di quest'ultimi.

Argomenti di particolare interesse:

- ricerca e sperimentazione clinica;
- neoplasie del distretto gastroenterico;
- terapie di supporto e terapie palliative;
- farmacoeconomia.

DIGITAL SKILLS-IT

My Digital Skills-IT

Gestione autonoma della posta e-mail | Social Network | Padronanza del Pacchetto Office (Word Excel PowerPoint ecc) | Utilizzo del browser | Windows

ORGANISATIONAL SKILLS-IT

Incarico professionale dirigenziale di alta specializzazione denominato "Ricerca e sperimentazioni oncologiche"

Referente di patologia relativo alle neoplasie del distretto gastroenterico per il Dipartimento Oncologico dell'Azienda ULSS 9 Scaligera

Referente dell'Area di Ricerca e Sperimentazione Clinica per il Dipartimento Oncologico dell'Azienda ULSS 9 Scaligera

Referente per l'Asl 9 Scaligera in merito all'Armonizzazione del progetto per il sistema informativo della Rete Oncologica Veneta con il progetto per il nuovo sistema informativo Ospedaliero (SIO)

Superutente per il nuovo SIO

COMPETENZE TECNICHE

[Current-IT]

Parametrizzatore degli schemi di trattamento medico oncologico del sistema informativo oncologico del Presidio Ospedaliero di Legnago (VR) (Oncosys)

CURE PALLIATIVE

[17/02/2022 – Current-IT]

Oncologo con certificata esperienza nell'ambito delle cure palliative

istanza di rilascio da parte della Giunta Regionale della Regione Veneto (Prot. N. 0073783 del 17/02/2022). L'attività in ambito di cure palliative è inoltre attestata dalla certificazione ESMO di Designated Center of Integrated Oncology and Palliative Care dell'U.O.C. di Oncologia Medica di appartenenza in qualità di medico oncologo palliativista.

Socio dell'Associazione Italiana di Oncologia Medica (AIOM)

membro del Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

membro dell'European Organisation for Research and Treatment of Cancer (EORTC) Endocrine Tumors Group

membro dell'EORTC Gastrointestinal Tract Cancer Group

membro dell'EORTC Genito-Urinary Cancer Group

membro dell'EORTC Head & Neck Cancer Group

membro dell'EORTC Lung Cancer Group

membro dell'EORTC Pathobiology Group

membro dell'EORTC Quality of Life Group

membro del Pharmacology and Molecular Mechanisms (PAMM) group of the EORTC

RICERCA CLINICA

[Current-IT]

Partecipazione scientifica a diversi protocolli di ricerca a carattere nazionale ed internazionale (prevalentemente Trial di fase II e III in Good Clinical Practice (GCP)).

In particolare, dal 2013 ho seguito 25 Trial con il ruolo di Sub Investigator (SI) (17 studi di fase III, 4 studi di fase II e 4 studi osservazionali) e 7 Trial con il ruolo di Principal Investigator (PI) (2 studi di fase III, 3 studi di fase II, 1 studio di fase IV ed 1 studio osservazionale) nelle principali neoplasie (colon-retto (5 studi), polmone (7 studi), testa-collo (4 studi), mammella (10 studi), prostata (1 studio), stomaco (1 studio), encefalo (1 studio), ovaio (1 studio), terapia di supporto (1 studio), ricerca traslazione (2 studi)), Certificazioni di GCP-training (ultima certificazione ottenuta il 20/02/2023).

Attività pubblicistica

Notevole affinità con il campo della Ricerca in Oncologia con una notevole attività pubblicistica: 130 documenti recensiti da Scopus, 525 citazioni, h-index (scopus)= 13, 80% first-Author, 1% last Author, 7% single Author, FWCI= 0.622, 3.5% di International Collaborations, 0.9% Academic-corporate Collaboration, 27.8% di pubblicazioni in riviste Q1 (dati ricavati da Scopus in data 23/05/2024).

ESPERIENZA EDITORIALE

[Current-IT]

Componente dell'Editorial Board, full member (2020-2022) della Rivista Internazionale "Gastrointestinal Stromal Tumor (GIST)"

Componente dell'Editorial Board, full member (2021-in corso) della Rivista Internazionale "Pharmaceutics"

Elenco Riviste più quotate: Drugs; Clinical Genitourinary Cancer; Thoracic Cancer; Clinical Breast Cancer; European Journal of Surgical Oncology; British Journal of Cancer; Onco Targets and Therapy; Lancet Oncology; Cancer Management and Research.

PUBLICATIONS-IT

- [2023] **HTA and Gastric Cancer: Evaluating Alternatives in Third- and Fourth-Line Patients.**
Reference-IT: Ferrario L, Asperti F, Aprile G, Giuliani J. Int J Environ Res Public Health 2023;20:2107
- [2023] **Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.**
Reference-IT: Giuliani J, et al. J Oncol Pharm Pract. 2023;29:457-464.
- [2023] **Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer**
Reference-IT: Giuliani J et al. J Oncol Pharm Pract. 2023;29:958-961.
- [2023] **The screening with the liquid biopsy for the rechallenge with anti-epidermal growth factor receptor antibodies in metastatic colorectal cancer A perspective based on pharmacological costs**
Reference-IT: Giuliani J et al. Recenti Prog Med. 2023;114:563-564.
- [2023] **Cost Effectiveness of Magnetic Resonance Imaging Guidance Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy**
Reference-IT: Giuliani J et al. Eur Urol Oncol. 2023. doi: 10.1016/j.euo.2023.09.003.
- [2023] **Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy**
Reference-IT: Giuliani J et al. Clin Colorectal Cancer. 2023. doi: 10.1016/j.clcc.2023.10.005.
- [2022] **Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer.**
Reference-IT: Giuliani J, J Oncol Pharm Pract. 2022. doi: 10.1177/10781552221114300.
- [2022] **Cost-effectiveness of programmed death ligand-1 (PD-L1) blockade in first-line for metastatic gastric/gastroesophageal junction cancer**
Reference-IT: Giuliani J, Mantoan B, Bonetti A. Eur J Cancer 2022;175: 193-195.
- [2022] **Whey proteins isolate supplementation in additional to nutritional counseling in cancer patients.**
Reference-IT: Giuliani J et al. Recenti Prog Med 2022; 113: 383-384.
- [2022] **Long-term survivors of metastatic colorectal cancer treated with trifluridine/ tipiracil.**
Reference-IT: Giuliani J, Mantoan B, Bonetti. Recenti Prog Med 2022; 113: 380-382.

- [2021] **Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.**
Reference-IT: Giuliani J et al. Clin Colorectal Cancer 2021. doi: 10.1016/j.clcc.2021.11.012.
- [2021] **The optimal duration of immune checkpoint inhibitors in non-oncogene addicted non-small cell lung cancer: less is more? An open question.**
Reference-IT: Giuliani J et al. Recenti Prog Med. 2021; 112: 802-804.
- [2021] **Alectinib in first-line treatment for advanced anaplastic lymphoma kinase mutation-positive (alk+) non-small cell lung cancer (NSCLC): a cost-effective change.**
Reference-IT: Giuliani J, Bonetti A. Recenti Prog Med 2021;112:472-5.
- [2021] **Implications of drugs with rebate in Europe.**
Reference-IT: Bonetti A, Giuliani J. Lancet Reg Health Eur 2021;;3:100060.
- [2021] **Cost-effectiveness of consolidation durvalumab after chemo-radiotherapy in stage III non-small-cell lung cancer: A cost-effective change.**
Reference-IT: Giuliani J et al. J Oncol Pharm Pract. 2021; 28: 438-441.
Scrivi qui la descrizione...
- [2021] **Cost-effectiveness of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancer.**
Reference-IT: Giuliani J, Florica F. J Oncol Pharm Pract. 2021. doi: 10.1177/10781552211038925.
- [2021] **The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma.**
Reference-IT: Giuliani J, Mantoan B, Bonetti A. J Oncol Pharm Pract. 2021. doi: 10.1177/10781552211045013.
- [2021] **Cost-effectiveness of denosumab in preventing skeletal-related events in bone metastases**
Reference-IT: Giuliani J. J Oncol Pharm Pract. 2021. doi: 10.1177/10781552211038002.
- [2021] **Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer.**
Reference-IT: Giuliani J, Mantoan B, Bonetti A. J Oncol Pharm Pract. 2021. doi: 10.1177/10781552211045006.
- [2021] **Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer.**
Reference-IT: Giuliani J, Mantoan B, Bonetti A. J Oncol Pharm Pract 2021. doi: 10.1177/10781552211038929.
- [2021] **Design your strategy, define your costs: third or subsequent-lines in advanced gastrointestinal stromal tumors (GIST).**
Reference-IT: Giuliani J. GIST 2021. doi: 10.21037/gist-21-5.
- [2021] **Cost-effectiveness of pembrolizumab in combination with platinum-based chemotherapy in first-line for squamous and non-squamous non-small cell lung cancer. Far from economic sustainability.**
Reference-IT: Giuliani J, Bonetti A. EJMO 2021; 5: 59-62.

- [2021] **Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer.**
Reference-IT: Giuliani J, Bonetti A. *Cancer Drug Resist* 2021;4:740-744.
- [2021] **Cost-effectiveness of SpaceOAR system during prostate cancer radiation therapy: Really helpful or excess of expectations?**
Reference-IT: Giuliani J, Fiorica F. *Brachytherapy* 2021. doi: 10.1016/j.brachy.2021.05.002.
- [2021] **The effect of COVID-19 pandemic on daily oncology clinical practice.**
Reference-IT: Codacci Pisanelli G, Giuliani J, Bonetti A. *Crit Rev Oncol Hematol* 2021;167:103272.
- [2021] **What to Do and What Not to Do in the Management of Cancer Pain: A Physician Survey and Expert Recommendations.**
Reference-IT: Bossi P, Antonuzzo A, Armento G, Consoli F, Giuliani J, et al. *Cancer Manag Res* 2021;13:5203-10.
- [2021] **Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report.**
Reference-IT: Fiorica F, Belluomini L, Giuliani J, et al. *Immunotherapy* 2021. doi: 10.2217/imt-2021-0039.
- [2021] **The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level.**
Reference-IT: Giuliani J, Mantoan B, Bonetti A. *J Oncol Pharm Pract* 2021. doi: 10.1177/10781552211019462.
- [2021] **Computerization during the antineoplastic compounding process guarantees greater adherence to evidence-based medicine for the prophylaxis of chemotherapy-induced nausea and vomiting.**
Reference-IT: Giuliani J et al. *Recenti Prog Med* 2021;112:470-1.
- [2021] **Covid-19 patients with cancer: what do they risk? Clinical, radiological and therapeutic features.**
Reference-IT: Giuliani J, Mantoan B, Bonetti A. *Recenti Prog Med* 2021;112:476-81.
- [2021] **Psychological impact of Covid-19 pandemic on oncological patients: A survey in Northern Italy**
Reference-IT: Pigozzi E et al. *PLoS One* 2021;16:e0248714.
- [2021] **The process of EUSOMA certification improves the quality of breast cancer care: the experience of an Italian EUSOMA certificated Breast Unit (BU) according to the results of a cross-sectional study.**
Reference-IT: Gazzani D et al. *Recenti Prog Med* 2021;112:458-64.
- [2021] **Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer.**
Reference-IT: Fiorica et al. *Cancers (Basel)* 2021;13:2352.
- [2021] **Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.**
Reference-IT: Giuliani J et al. *J Oncol Pharm Pract* 2021. doi: 10.1177/1078155221992546.

- [2021] **Radiotherapy in cancer and rheumatoid arthritis patients: cancer treatment or control of articular flares? We can achieve both.**
Reference-IT: Fiorica F, Ciancio G, Giuliani J et al. Eur Rev Med Pharmacol Sci 2021;25:1548-56.
Scrivi qui la descrizione...
- [2021] **The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs.**
Reference-IT: Giuliani J et al. J Oncol Pharm Pract 2021;27:445-7.
- [2021] **Financial toxicity and cancer treatments: Help from biosimilars - The explanatory case of bevacizumab.**
Reference-IT: Giuliani J et al. Eur J Cancer. 2021;143:40-42.
- [2021] **To perform genotyping of dihydropyrimidine dehydrogenase (DPD) before starting treatment with 5-fluorouracil or related medicines: really feasible?**
Reference-IT: Giuliani J, Bonetti A. Int J Colorectal Dis 2021;36:197-8
- [2021] **The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence.**
Reference-IT: Giuliani J, Bonetti A. Breast J 2021;27:75-6.
- [2021] **Cancer prevales on COVID-19: To maintain high quality standard concerning diagnosis and oncological care even during a pandemic.**
Reference-IT: Giuliani J, Bonetti A. J Med Virol 2021;93:118-9.
- [2020] **Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costs.**
Reference-IT: Giuliani J, Bonetti A. Eur J Cancer 2020;138:77-9.
- [2020] **Cost-effectiveness of Newer Regimens for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting: Review of the Literature and Real-World Data.**
Reference-IT: Giuliani J, Bonetti A. Curr Opin Oncol 2020;32:269-273.
- [2020] **The Introduction of a Third CDK4/6 Inhibitor Does Not Change the Cost-Effectiveness Profile in First and Subsequent-Lines After Progression or Relapse During Previous Endocrine Therapy in Patients With Hormone Receptor Positive (HR+)/human Epidermal receptor-2 Negative (HER-2) Advanced or Metastatic Breast Cancer.**
Reference-IT: Giuliani J, Bonetti A. J Oncol Pharm Pract 2020;26: 1486-91.
- [2020] **Glioblastoma: Prognostic Factors and Predictive Response to Radio and Chemotherapy.**
Reference-IT: Fiorica F, Colella M, Taibi R, Bonetti A, Giuliani J et al. Curr Med Chem 2020;27: 2814-2825.
- [2020] **Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real Life.**
Reference-IT: Giuliani J, Bonetti A. Clin Colorectal Cancer 2020. doi: 10.1016/j.clcc.2020.04.004.

- [2019] **Light and Shadow on Innovative Clinical Trial Designs: Reflections From the EORTC-PAMM Course on 'Preclinical and Early-Phase Clinical Pharmacology'.**
Reference-IT: Leonetti A, Boyd L, Giuliani J et al. Expert Rev Clin Pharmacol 2019;12: 1033-1036.
- [2019] **Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level**
Reference-IT: Giuliani J, Bonetti A. Oral Oncol 2019;97: 143-145.
- [2019] **Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment.**
Reference-IT: Giuliani J, Bonetti A. Pharmacoecon Outcomes Res 2019. doi: 10.1080/14737167.2019.1650644.
Scrivi qui la descrizione,...
- [2019] **The exposure to perfluoroalkyl substances (PFAS) and the development of cancer.**
Reference-IT: Giuliani J, Bonetti A. Recenti Prog Med 2019;110: 368-370
- [2019] **The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.**
Reference-IT: Giuliani J, Bonetti A. Anticancer Res 2019;39: 3971-3973.
- [2019] **The Onset of Grade ≥ 3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil.**
Reference-IT: Giuliani J, Bonetti A. Anticancer Res 2019;39: 3967-3969.
- [2019] **Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors.**
Reference-IT: Giuliani J, Bonetti A. Anticancer Res 2019;39: 3961-3965.
- [2019] **Economic sustainability of nivolumab at flat dose for second-line treatment of metastatic non-small cell lung cancer in real life.**
Reference-IT: Giuliani J et al. J Oncol Pharm Pract 2019. doi: 10.1177/1078155219854125.
- [2019] **Immunotherapy in first-line for advance non-small cell lung cancer: a cost-effective choice?**
Reference-IT: Giuliani J, Bonetti A. Recenti Prog Med 2019;110: 138-143.
- [2019] **Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor-Positive/Human Epidermal Receptor 2-Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs.**
Reference-IT: Giuliani J, Bonetti A. Clin Breast Cancer 2019. doi: 10.1016/j.clbc.2019.02.004.
- [2019] **FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic cancer**
Reference-IT: Giuliani J, Bonetti A. Pancreatology 2019; 19: 325-330.
- [2019] **Colonic Ewing Sarcoma/PNET associated with liver metastases: A systematic review and case report.**

Reference-IT: Parcesèpe P, Giordano G, Zanella C, Giuliani J et al. Pathol Res Pract 2019; 215: 387-391.

[2018] **Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma.**

Reference-IT: Giuliani J, Bonetti A. Clin Genitourin Cancer 2018. doi: 10.1016/j.clgc.2018.11.010.

[2018] **Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018.**

Reference-IT: Giuliani J, Bonetti A. Eur J Cancer 2018; doi: 10.1016/j.ejca.2018.08.026.

[2018] **First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs.**

Reference-IT: Giuliani J, Bonetti A. Int J Colorectal Dis 2018. doi: 10.1007/s00384-018-3158-8.

[2018] **Long-term survival in advanced pancreatic cancer**

Reference-IT: Giuliani J, Bonetti A. Recenti Prog Med 2018; 109: 352-358.

[2018] **Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs.**

Reference-IT: Giuliani J, Bonetti A. Int J Colorectal Dis 2018. doi: 10.1007/s00384-018-3077-8.

[2018] **Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs.**

Reference-IT: Giuliani J, Bonetti A. Clin Colorectal Cancer 2018; 17: e381-e383.

[2018] **Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma.**

Reference-IT: Giuliani J, Bonetti A. Clin Genitourin Cancer 2018. doi: 10.1016/j.clgc.2018.02.006.

[2017] **The gemcitabine and oxaliplatin (GEMOX) for the advanced pancreatic cancer: the reports of my death have been greatly exaggerated?**

Reference-IT: Giuliani J, Bonetti A. Recenti Prog Med 2017; 108: 521-527.

[2017] **Second-line treatment in metastatic renal cell carcinoma. Can immunotherapy be considered a cost-effective treatment?**

Reference-IT: Giuliani J, Bonetti A. Eur Urol 2017. doi:10.1016/j.eururo.2017.10.010.

[2017] **The pharmacological costs of second-line treatments for recurrent ovarian cancer**

Reference-IT: Giuliani J, Bonetti A. Int J Gynecol Cancer 2017. doi: 10.1097/IGC.0000000000001106.

[2017] **Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costs.**

Reference-IT: Giuliani J, Bonetti A. Expert Rev Pharmacoecon Outcomes Res 2017; 17: 243-248.

[2017] **Cost-effectiveness of first-line hormone-therapies in chemonaïve castration-resistant prostate cancer Integrating the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) with the costs of drugs.**

Reference-IT: Giuliani J, Bonetti A. Recenti Prog Med 2017; 108: 294-295.

- [2017] **Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs.**
Reference-IT: Giuliani J, Bonetti A. Clin Lung Cancer 2017; 18: e363-365.
- [2017] **Elderly patients with advanced pancreatic cancer: the generalizability of the results of clinical trials to daily clinical practice.**
Reference-IT: Giuliani J, Bonetti A. Recenti Prog Med 2017; 108: 152-154.
- [2016] **The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations**
Reference-IT: Giuliani J, Remo A, Bonetti A. Expert Rev Pharmacoecon Outcomes Res 2016; 21: 1-4.
Scrivi qui la descrizione...
- [2016] **The Pharmacological Costs of First-Line Therapies in Unselected Patients With Advanced Colorectal Cancer: A Review of Published Phase III Trials.**
Reference-IT: Giuliani J, Bonetti A. Clin Colorectal Cancer 2016; 15: 277-284.
- [2016] **The Pharmacological Costs for the Management of Skin Toxicity in Patients With Cancer Treated With Epidermal Growth Factor Receptor-Inhibitors.**
Reference-IT: Giuliani J, Bonetti A. Clin Lung Cancer 2016; 17: 471-473.
- [2016] **The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients treated with targeted agents.**
Reference-IT: Giuliani J, Bonetti A. Recenti Prog Med 2016; 107: 434-439.
- [2016] **The Pharmacological Costs of Complete Liver Resections in Unselected Advanced Colorectal Cancer Patients: Focus on Targeted Agents. A Review of Randomized Clinical Trials.**
Reference-IT: Giuliani J, Bonetti A. J Gastrointest Cancer 2016. DOI: DOI.10.1007/s12029-016-9862-0.
- [2016] **The development of hypertension in metastatic colorectal cancer patients treated with aflibercept: the role of systolic and diastolic blood pressure before starting treatment.**
Reference-IT: Giuliani J, Bonetti A. Recenti Prog Med 2016; 107: 199-200.
- [2016] **The role of palliative surgery in the management of advanced pancreatic cancer in patients with biliary and duodenal obstruction.**
Reference-IT: Giuliani J, Bonetti A. Eur J Surg Oncol 2016; 42: 581-583.
- [2016] **Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials.**
Reference-IT: Giuliani J, Bonetti A. Clin Lung Cancer 2016; 17: 91-94.
- [2016] **Second-Line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer.**
Reference-IT: Giuliani J, Bonetti A. Clin Lung Cancer 2016; 17: e25-27.

- [2016.] **Case Report of a Well-Differentiated Papillary Mesothelioma of the Tunica Vaginalis In an Undescended Testis With Review of Literature.**
Reference-IT: Parcesepe P et al. Int J Surg Pathol 2016. DOI: 10.1177/1066896916628279.
- [2016.] **The Multidisciplinary Management of Cancer in Daily Clinical Practice: Towards a Community Hospital Comprehensive Cancer Center.**
Reference-IT: Giuliani J, Bonetti A. J Gastrointest Cancer 2016; 47: 123-124.
- [2016.] **Cisplatin versus cetuximab given concomitantly with radiotherapy in non-resectable head and neck squamous carcinoma: an open question.**
Reference-IT: Giuliani J, Bonetti A. Eur Arch Otorhinolaryngol 2016; 273: 263-265.
- [2015.] **Platinum antitumor complexes.**
Reference-IT: Bonetti A, Giuliani J, Muggia F. Recenti Prog Med 2015; 106: 618-628.
- [2015.] **Late recurrence (more than 10 years) in early (tumor equal to or smaller than 2 cm) breast cancer patients.**
Reference-IT: Giuliani J, Mercanti A, Bonetti A. Clin Transl Oncol 2015. DOI: 10.1007/s12094-015-1433-1435.
- [2015.] **Management of advanced pancreatic cancer in daily clinical practice.**
Reference-IT: Giuliani J, Piacentini P, Bonetti A. Tumori 2015. DOI: 10.5301/tj.5000428.
- [2015.] **The Occurrence of Gastrointestinal Stromal Tumors and Second Malignancies.**
Reference-IT: Giuliani J, Bonetti A. J Gastrointest Cancer 2015; 46: 408-412.
- [2015.] **Acute Liver Failure Caused by Metastatic Breast Cancer: Can We Expect Some Results from Chemotherapy?**
Reference-IT: Giuliani J, Bonetti A. Dig Dis Sci 2015; 60: 2541-2543.
- [2015.] **Trends in survival for patients with metastatic breast cancer: is survival improving?**
Reference-IT: Giuliani J, Bonetti A. Tumori 2015; 101: 347-352.
- [2015.] **Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.**
Reference-IT: Giuliani J, Martelli S, Remo A, Bonetti A. Tumori 2015; 101: e115-117.
- [2015.] **Ampulla of Vater Carcinoma in real world clinical practice: a case series.**
Reference-IT: Giuliani J, Piacentini P, Bonetti A. Tumori 2015; 101: e75-78.
- [2015.] **Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a real "pan-thrombosis"**
Reference-IT: Giuliani J, Martelli S, Piacentini P, Bonetti A. Tumori 2015. DOI: 10.5301/tj.5000258.
- [2015.] **The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients: a review of published Phase II and III trials.**
Reference-IT: Giuliani J et al. Expert Rev Pharmacoecon Outcomes Res 2015; 15:101-110.
- [2014.] **A path for diagnosis and therapy of colon cancer: a continuous quality improvement.**
Reference-IT: Giuliani J, Marzola M. Chin J Cancer Res 2014; 26: 717-723.

- [2014] **The outcome of targeted therapies in patients with poor prognosis metastatic renal cell carcinoma.**
Reference-IT: Giuliani J, Marzola M. Cancer Biother Radiopharm 2014; 29: 298-300.
- [2014] **Is there a real need of adjuvant chemotherapy for locally advanced nasopharyngeal carcinoma?**
Reference-IT: Giuliani J, Marzola M. J Gastrointest Canc 2014;45: 396-397.
- [2014] **The coexistence of second and third malignancies in adult-onset cancer patients.**
Reference-IT: Giuliani J, J Gastrointest Canc 2014;45: 395.
- [2014] **Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer.**
Reference-IT: Bonetti A, Giuliani J, Muggia F. Anticancer Res 2014;34: 423-434.
- [2014] **Carboplatin-containing regimens as front-line treatment for advanced non-small cell lung cancer in two groups of elderly.**
Reference-IT: Giuliani J, et al. J Chemoth 2014; 26: 111-116.
- [2014] **Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?**
Reference-IT: Giuliani J, Marzola M. Cent Eur J Med 2014; 9: 279-284.
- [2014] **Intraperitoneal hyperthermic chemotherapy: which drugs?**
Reference-IT: Giuliani J. J Gastrointest Canc 2014; 45: 113-115.
- [2013] **Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate.**
Reference-IT: Giuliani J, Bonetti A. Chin J Cancer Res 2013; 25: 486-487.
- [2013] **Platinum doublets as first-line treatment for elderly patients with advanced non-small cell lung cancer.**
Reference-IT: Piacentini P et al. Tumori 2013; 99: 610-615.
- [2013] **Spinal tuberculosis simulating metastatic malignancy: an unusual condition.**
Reference-IT: Giuliani J, Urbini B. Asian Pac J Trop Med 2014;7: 83-84.
- [2013] **Off-label oncology prescription in Italy: a legal perspective.**
Reference-IT: Giuliani J, Maioli V, Bonetti A. Eur J Oncol 2013; 18: 85-91.
- [2013] **Palliative surgery in the multidisciplinary management of the advanced ovarian cancer.**
Reference-IT: Giuliani J. J Pall Med 2013; 17: 6-7.
- [2013] **Cancer related symptoms in homecare cancer patients: which impact in daily clinical practice?**
Reference-IT: Giuliani J, Busatto A. Med Oncol 2013; 30: 365.
- [2013] **The effect of palliative care on the assistance of terminally ill cancer patients.**
Reference-IT: Giuliani J et al. J Pall Med 2013; 16: 826-827.
- [2013] **Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?**

- Reference-IT: Giuliani J, Marzola M. Arch Dermatol Res 2013; 305: 653-658.
- [2013] Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?
- Reference-IT: Giuliani J, Marzola M. J Gastrointest Canc 2013; 44: 241-245.
- [2013] Intravenous midline catheter usage: which clinical impact in homecare patients?
- Reference-IT: Giuliani J et al. J Palliat Med 2013. DOI: 10.1089/jpm.2012.0615.
- [2013] Off-label prescription of anti-cancer drugs in italy: what responsibilities?
- Reference-IT: Giuliani J, Maioli V, Bonetti A. Tumori 2013; 99: e190-e192.
- [2013] Pancreatic carcinoma radically resected and adjuvant treatment. A review of literature.
- Reference-IT: Drudi F, Tassinari D, Giuliani J et al. Recenti Prog Med 2013; 104: 80-5.
- [2013] Single-agent bevacizumab as maintenance therapy in metastatic colorectal cancer: how long do we have to continue?
- Reference-IT: Giuliani J, Marzola M. Memo 2013; 6: 147-8.
- [2013] The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
- Reference-IT: Giuliani J, Marzola M. Cutan Ocul Toxicol 2013; DOI: 10.3109/15569527.2013.765444.
- [2013] Multidisciplinary Approach as the Key factor in the Management of Liver Metastases from Colorectal Cancer.
- Reference-IT: Giuliani J, Marzola M. J Gastrointest Canc 2013; 44: 486-488.
- [2013] Liver Metastases from Primary Rectal Cancer: A Multidisciplinary Reverse Approach.
- Reference-IT: Giuliani J, Marzola M, Pansini G. J Gastrointest Canc 2013; 44: 368-369.
- [2013] Primary malignant fibrous histiocytoma of Vater's papilla: first reported case.
- Reference-IT: Giuliani J. J Gastrointest Canc 2013; 44: 366-367.
- [2012] The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospective economical assessment from a mono-Institutional experience.
- Reference-IT: Giuliani J, Indelli M, Marzola M, Raisi E, Frassoldati A. Tumori 2012; 98: 408-412.
- [2012] Ovarian endometrioid adenocarcinoma with a yolk sac tumor component in a postmenopausal women: case report and review of the literature.
- Reference-IT: Giuliani J et al. Clin Ovarian Cancer Other Gynecol Malig 2012; 5: 31-32.
- [2012] Ovarian cancer in elderly patients: a difference in treatment based on age?
- Reference-IT: Giuliani J, Drudi F. Arch Gynecol Obstet 2012; 286: 1545-1548.
- [2012] A severe delayed infusion reaction induced by trastuzumab: a life-threatening condition.
- Reference-IT: Giuliani J et al. Med Oncol 2012; 29: 3597-3598.

- Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials
[2024]
Reference-IT: Tucci M, Mandarà M, Giuliani J et al. Cancer Treat Rev 2024; 127: 102745.
Write here the description...-IT
- Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence?
[2012]
Reference-IT: Giuliani J, Drudi F. Cancer Biother Radiopharm 2012; 27: 513-518.
- Oncological quality indicators and Colorectal Cancer Program: data from 2009-2010 of University Hospital in Ferrara, Italy.
[2012]
Reference-IT: Giuliani J, Marzola M, Indelli M, Frassoldati A. Recenti Prog Med 2012; 103: 56-61.
- Gastrointestinal Stromal Tumors and Other Malignancies: a Case Series.
[2012]
Reference-IT: Giuliani J et al. J Gastrointest Canc 2012; 43: 634-637.
Scrivi qui la descrizione...
- Benign multicystic peritoneal mesothelioma: cases report and review of the literature.
[2010]
Reference-IT: Giuliani J et al. Eur J Oncol 2010; 15: 119-123.
- Prognostic and predictive factors related to metastatic breast cancer clinical history: an outcome study.
[2007]
Reference-IT: Giuliani J et al. Eur J Oncol 2007; 12: 259-266.

ABSTRACTS/COMUNICAZIONI A CONGRESSI NAZIONALI/INTERNAZIONALI

46 comunicazioni in totale (di cui 36 come primo nome)

PARTECIPAZIONE IN QUALITÀ DI RELATORE SU INVITO A CONGRESSI/SEMINARI

24 eventi in totale

LINEE GUIDA

Coautore delle Linee Guida dell'Azienda ULSS 21 di Legnago per la terapia medica del dolore oncologico.

PARTECIPAZIONE IN QUALITÀ DI AUDITORE A CORSI/CONGRESSI NAZIONALI ED INTERNAZIONALI

164 eventi in totale

Componente della Commissione sanità Pubblica e Ospedale San Luca di Trecenta (RO) (2014-2018)

Componente in qualità di Segretario della Commissione sanità Pubblica e Ospedale San Luca di Trecenta (RO) (2014-2018), come da decreti di nomina (Prot. N. 2108 del 21/02/2014 del Comune di Trecenta (RO) e regolamento comunale della suddetta commissione. La Commissione Sanità Pubblica e Ospedale S. Luca costituiva un organo a carattere consultivo e svolgeva i seguenti compiti e funzioni: esprimeva pareri su proposte o questioni inerenti la sanità pubblica e Ospedale S. Luca sottoposte alla stessa dalla Giunta e dal Consiglio Comunale, svolgeva attività di monitoraggio dei servizi offerti dall'Ospedale S. Luca per testarne l'adeguatezza e la qualità percepita dai cittadini, promuoveva indagini, ricerche e studi relativi alle materie di sua competenza, e favoriva, per quanto possibile, la partecipazione dei cittadini, formulava proposte o quesiti da sottoporre alla Giunta in ordine ad interventi o iniziative da attuare nel settore di sua pertinenza.

Il sottoscritto Dr. Jacopo Giuliani sotto la propria responsabilità e consapevole delle sanzioni penali previste nel caso di dichiarazioni mendaci, richiamate all'art.76 del DPR 445 del 28/12/2000 e della decadenza dai benefici eventualmente conseguenti al provvedimento emanato sulla base di dichiarazioni non veritiere, dichiara che il contenuto di questo Curriculum Vitae (CV) è conforme al vero. Autorizzo il trattamento dei miei dati personali secondo la Legge Italiana sulla privacy 196/03.

LEGNAGO (VI), 16/08/2024